T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1/2
21
about 3.6 years
18+
2 sites in CA, TX
What this study is about
This trial is testing a new treatment called EB103 for adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. The goal is to determine how safe this treatment is and what dose works best.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive EB103
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence rates of Treatment-Emergent Adverse Events of EB103.
Secondary: To assess the Disease Control Rate of EB103 in our study subject population., To assess the Duration of Response of EB103 in our study subject population., To assess the Event-Free Survival rate of EB103 in our study subject population., To assess the Overall Response Rate of EB103 in our study subject population., To assess the Overall Survival rate of EB103 in our study subject population., To assess the Progression-Free Survival rate of EB103 in our study subject population., To characterize the pharmacokinetic (PK) profile of EB103 by measuring the partial area under the curve (pAUC)., To characterize the pharmacokinetic (PK) profile of EB103 by measuring the peak exposure (Cmax).
Oncology